Biodesix expands Series E funding stash for personalized lung cancer treatment Dx

Colorado molecular diagnostics outfit Biodesix has come close to doubling a Series E financing that it first announced in December. The company, which is developing a personalized medicine-focused lung cancer test, initially raised $8.3 million for the round in a mix of both new funding and the conversion of a convertible note. But Biodesix has now pulled in another $6.1 million from a follow-on sale of preferred shares. Execs plan on using the now-$14.4 million cash infusion to help advance its VeriStrat serum protein test that helps physicians figure out the best treatment for patients with advanced non-small cell lung cancer. Item

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.